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ABSTRACT
The goal of anticancer therapy is to selectively eradicate all malignant cells. 
Unfortunately for the majority of patients with metastatic disease, this goal 
is consistently thwarted by the nearly inevitable development of therapeutic 
resistance; the main driver of therapeutic resistance is a minority subpopulation of 
cancer cells called cancer stem cells (CSCs) whose mitotic quiescence essentially 
renders them non-eradicable. The Wnt signaling pathway has been widely implicated 
as a regulator of CSCs and, therefore, its inhibition is thought to result in a reversal 
of therapeutic resistance via loss of stem cell properties. 
RRx-001 is a minimally toxic redox-active epi-immunotherapeutic anticancer 
agent in Phase III clinical trials that sensitizes tumors to radiation and cytotoxic 
chemotherapies. In this article, as a potential mechanism for its radio- and 
chemosensitizing activity, we report that RRx-001 targets CD133+/CD44+ cancer 
stem cells from three colon cancer cell-lines, HT-29, Caco-2, and HCT116, and 
inhibits Wnt pathway signalling with downregulation of c-Myc. 
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INTRODUCTION
The c-Myc (Myc) oncoprotein is a well-established 
driver of breast, lung, colorectal and prostate cancers 
that is currently considered “undruggable” [1–4]. Myc 
overexpression is associated with cancer stem cell 
maintenance [5] and, by extension, with therapeutic 
resistance since cancer stem cells are thought to be the 
primary mediators of tumor resistance and progression. 
RRx-001 is a first-in-class minimally toxic epi-
immunotherapeutic agent in Phase III clinical trials as a 
chemosensitizer to reverse resistance in small cell lung 
cancer (SCLC), high-grade neuroendocrine carcinomas 
(HGNEC) and colorectal cancers [6].
Herein, as a potential mechanism for its radio- and 
chemosensitizing activity, we demonstrate for the first 
time that RRx-001 targets cancer stem cells (CSCs) and 
that it decreases the expression levels of Wnt pathway 
components and target genes, such as TCF4, Pygo2, Axin2 
and c-Myc, which are known to govern stem cell renewal 
and differentiation [7, 8]. 
RESULTS
RRx-001 selectively targets colon CSCs
CD133 and CD44 are widely considered as markers 
of cancer stem/progenitor-like cells. In order to determine 
the effect of RRx-001 on both cancer and CSC cell 
proliferation, an MTT assay was performed. 
Results of the flow cytometric assay depicted that 
after 3-day treatment, RRx-001 reduced the CD133+/
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CD44+ population in a time-dependent manner in all three 
cell lines. The extent of reduction was less than that of 
non-CSC cancer cells (Figure 1). 
RRx-001 downregulates components of the Wnt 
pathway
To test the hypothesis that downregulation of the 
Wnt signalling pathway is responsible for the reduced CSC 
growth, since the Wnt signaling pathway is reported to sustain 
self-renewal potential and chemoresistance in CSCs [9, 10], 
the impact of RRx-001 on the Wnt pathway was investigated. 
(Figure 2) As shown in Figure 3, RRx-001 dramatically 
decreased expression levels of Axin2 and c-Myc.
DISCUSSION
In light of the failure of currently available 
therapeutic options to eliminate CSCs, which are 
associated with treatment resistance and cancer recurrence, 
CSC-targeted therapies have the potential to usher in a 
new paradigm shift in oncology (Figure 3). 
MATERIALS AND METHODS
RRx-001
RRx-001, provided by EpicentRx, Inc, was diluted 
in dimethylsulfoxide (DMSO) to a 10 μM concentration.
Fluorescence-activated cell sorting (FACS) of 
cells
Colon cancer cell lines Caco-2, HT-29, and HCT-
116 were obtained from the American Type Culture 
Collection (ATCC, Rockville, MD, USA), and maintained 
according to the ATCC’s instructions. All culture reagents 
were from Invitrogen (Carlsbad, CA, USA). To analyze 
the expression of CD44 and CD133 in different lines, 
cells were treated with 10 μM RRx-001 for 72 hours, 
then trypsin-digested and re-suspended in stain buffer 
(1 × 106 cells in 80 μl). Cells were then treated with 20 
μl FcR Blocking Reagent for 15 min, and incubated 
with antibodies (human anti-CD44-FITC and human 
anti-CD133-PE) for 30 min. After staining, cells were 
subjected to flow cytometry.
To isolate CD44high/CD133high and CD44low/CD133low 
cells were trypsinized and blocked with FcR Blocking 
Reagent. Propidium iodide staining was applied to exclude 
the dead cells. Live cells were incubated with antibodies 
(human anti-CD44-FITC and human anti-CD133-APC) 
for 30 min. CD44low/CD133low and CD44high/CD133high 
cells were sorted by a cell sorter.
Cell proliferation measurement
The colon cancer cells were split into 96 well dishes 
at 2,000 cells per well. Cells were treated with 10 μM of 
RRx-001. Cell proliferation was evaluated using the MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium 
Figure 1: RRx-001 inhibits proliferation of colon cancer cells and stem cells in all three cell lines.
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Figure 2: Potential paradigm-shifting effect of a cancer stem cell (CSC) inhibitor on tumor chemoresistance.
Figure 3: Western blot of analysis of Wnt target genes with Wnt pathway shown to the right.
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bromide) assay at indicated days. The absorbance was 
measured at the wavelength of 570 nm. The measured 
optical density (OD) values were directly proportional to 
the number of viable cells. Then, 
dose-response curves were fitted to the data. All 
experiments were repeated at least three times.
Western blot for protein expression
Whole-cell lysates were separated by 10% SDS–
PAGE and proteins were analyzed by western blotting 
for the expression of Axin 2, c-Myc, β-catenin, Tcf4, and 
Pygo2. Actin was used as a loading control.
Statistical analysis
All data were presented as mean ± SD from three 
sets of independent experiments and analyzed using 
statistical software GraphPad Prism. Statistical differences 
between groups were determined by unpaired Student’s 
t-test or One-way Analysis of Variance (ANOVA); 
P < 0.05 was considered as statistical significance.
CONCLUSIONS
Herein, we demonstrate for the first time that RRx-
001 targets colon CSCs and inhibits multiple components 
of the self-renewal Wnt pathway including c-Myc. Since 
Myc is not an easily “druggable” protein, due to a lack of 
enzymatic activity or any small molecule-binding deep 
pockets [11], these results suggest that RRx-001 should 
be evaluated as a treatment for c-Myc-overexpressing 
tumors. 
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